{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:17:38Z","timestamp":1791850658637,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.diagmicrobio.2020.115272","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T07:42:02Z","timestamp":1605858122000},"page":"115272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-0291","authenticated-orcid":false,"given":"Celeste","family":"Witting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7170-9760","authenticated-orcid":false,"given":"Jessica","family":"Quaggin-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-7609","authenticated-orcid":false,"given":"Ruben","family":"Mylvaganam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Peigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-7864","authenticated-orcid":false,"given":"Michael","family":"Angarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115272_bib0001","series-title":"Genentech, Inc.","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2020.115272_bib0002","doi-asserted-by":"crossref","unstructured":"Alanio A, Delli\u00e8re S, Fodil S, Bretagne S, M\u00e9garbane B. High prevalence of putative invasive pulmonary aspergillosis in critically ill COVID-19 patients. [Preprint]. 2020 [15th April 2020]. Available https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3575581","DOI":"10.2139\/ssrn.3575581"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2020.115272_bib0003","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3109\/13693786.2010.505204","article-title":"Clinical risk factors for invasive aspergillosis","volume":"49","author":"Baddley","year":"2011","journal-title":"Med Mycol"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2020.115272_bib0004","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3201\/eid2607.201603","article-title":"Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient","volume":"26","author":"Blaize","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115272_bib0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.diagmicrobio.2020.115272_bib0006","series-title":"Novel coronavirus pneumonia diagnosis and treatment plan","year":"2020"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2020.115272_bib0007","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-011-0488-6","article-title":"Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab","volume":"22","author":"Hoshi","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2020.115272_bib0008","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/crj.12995","article-title":"Invasive pulmonary aspergillosis in patients with influenza infection: a retrospective study and review of the literature","volume":"13","author":"Huang","year":"2019","journal-title":"Clin Resp J"},{"key":"10.1016\/j.diagmicrobio.2020.115272_bib0009","doi-asserted-by":"crossref","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 92(7):814\u2013818.","DOI":"10.1002\/jmv.25801"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115272_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.riam.2009.04.001","article-title":"Aspergillosis in patients treated with monoclonal antibodies","volume":"26","author":"Nedel","year":"2009","journal-title":"Rev Iberoam Micol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115272_bib0011","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115272_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-016-0572-1","article-title":"Fungal infections and new biologic therapies","volume":"18","author":"Vallabhaneni","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2020.115272_bib0013","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QCO.0000000000000504","article-title":"Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment","volume":"31","author":"Vanderbeke","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2020.115272_bib0014","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.diagmicrobio.2020.115272_bib0015","article-title":"Effective treatment of severe COVID-19 patients with Tocilizumab","author":"Xu","year":"2020","journal-title":"ChinaXiv"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115272_bib0016","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-1 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320306490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320306490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:55:02Z","timestamp":1760003702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320306490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0732889320306490"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115272","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115272"}}